Garcia HH, Nash TE, Del Brutto OH, 2014. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 13: 1202–1215.
Bustos JA, Coyle CM, 2020. Brain calcification because of neurocysticercosis: a vast field to be explored. Curr Opin Infect Dis 33: 334–338.
Velasco TR et al.2006. Calcified cysticercotic lesions and intractable epilepsy: a cross sectional study of 512 patients. J Neurol Neurosurg Psychiatry 77: 485–488.
Bianchin MM, Velasco TR, dos Santos AC, Sakamoto AC, 2012. On the relationship between neurocysticercosis and mesial temporal lobe epilepsy associated with hippocampal sclerosis: coincidence or a pathogenic relationship. Pathog Glob Health 106: 280–285.
Rathore C, Thomas B, Kesavadas C, Abrahan M, Radhakrishnan K, 2013. Calcified neurocysticercosis lesions and antiepileptic drug-resistant epilepsy: a surgically remediable syndrome? Epilepsia 54: 1815–1822.
Bianchin MM, Velasco TR, Wichert-Ana L, Alexandre V Jr, Araujo D Jr, dos Santos AC, Garlotti CG Jr, Takayanagui OM, Sakamoto AC, 2014. Characteristics of mesial temporal lobe epilepsy associated with hippocampal sclerosis plus neurocysticercosis. Epilepsy Res 108: 1889–1895.
Bianchin MM, 2015. Neuroimaging observations linking neurocysticercosis and mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsy Res 116: 34–39.
Del Brutto OH, Engel J Jr, Eliashiv DS, Salamon N, Garcia HH, 2014. Hippocampal sclerosis: the missing link of cysticercosis epileptogenesis? Epilepsia 55: 2077–2078.
Del Brutto OH, Engel J Jr, Eliashiv D, Garcia HH, 2016. Update on cysticercosis epileptogenesis: the role of the hippocampus. Curr Neurol Neurosci Rep 16: 1.
Bianchin MM, Velasco TR, Wichert-Ana L, dos Santos AC, Sakamoto AC, 2017. Understanding the association of neurocysticercosis and mesial temporal lobe epilepsy and its impact on the surgical treatment of patients with drug-resistant epilepsy. Epilepsy Behav 76: 168–177.
Del Brutto OH, Salgado P, Lama J, Del Brutto VJ, Campos X, Zambrano M, Garcia HH, 2015. Calcified neurocysticercosis associates with hippocampal atrophy: a population-based study. Am J Trop Med Hyg 92: 64–68.
Del Brutto OH, Issa NP, Salgado P, Del Brutto VJ, Zambrano M, Lama J, Garcia HH, 2017. The association between neurocysticercosis and hippocampal atrophy is related to age. Am J Trop Med Hyg 96: 243–248.
Garcia HH et al.2014. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 14: 687–695.
Fisher RS et al.2014. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55: 475–482.
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J, 1992. Atrophy of medical temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55: 967–972.
Del Brutto OH, Mera RM, Wu S, Recalde BY, Issa NP, 2021. Epilepsy, interictal EEG abnormalities and hippocampal atrophy in patients with calcified neurocysticercosis: a population study in an endemic milieu. Epileptic Disord 23: 357–365.
Boutet C, Chupin M, Colliot O, Sarazin M, Mutlu G, Drier A, Pellot A, Dormont D, Lehércy S, Alzheimer’s Disease Neuroimaging Initiative , 2012. Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer’s disease? Neuroradiology 54: 1321–1330.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||74||43||7|
Magnetic resonance images from 197 patients with calcified neurocysticercosis (NCC), 38 with viable NCC and 197 NCC-free healthy rural villagers were evaluated to compare the frequency of hippocampal atrophy/sclerosis (HAS) across these populations. Scheltens’ medial temporal atrophy scale was used for hippocampal rating. The median age of the 432 study participants was 46 years (interquartile range, 29–62 years), and 58% were women. Hippocampal atrophy/sclerosis was disclosed in 26.9% patients with calcified NCC, compared with 7.9% in patients with viable NCC and 8.1% in healthy rural villagers. After adjusting for age, gender, and history of epilepsy, hippocampal atrophy/sclerosis was more frequent in patients with calcified NCC than in those with viable cysts (RR, 3.60; 95% CI, 1.18– 0.99; P = 0.025) and healthy rural villagers (RR, 3.43; 95% CI, 1.94–6.06; P < 0.001), suggesting that hippocampal damage develops late in the course of this parasitic disease.
Financial support: This work was supported in part by the Fogarty International Center/National Institutes of Health Training grant TW001140 and by the Universidad Espíritu Santo, Ecuador.
Authors’ addresses: Sofía S. Sánchez, Center for Global Health, Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru, E-mail: firstname.lastname@example.org. Javier A. Bustos and Héctor H. Garcia, Center for Global Health, Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru, and Cysticercosis Unit, Instituto Nacional de Ciencias Neurológicas, Lima, Peru, E-mails: email@example.com and firstname.lastname@example.org. Oscar H. Del Brutto, School of Medicine, Universidad Espíritu Santo–Ecuador, Samborondón, Ecuador, E-mail: email@example.com. Genaro Herrera, Isidro Gonzales, and Herbert Saavedra, Cysticercosis Unit, Instituto Nacional de Ciencias Neurológicas, Lima, Peru, E-mails: firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Antonio Carlos dos Santos, Centro de Cirurgia de Epilepsia, Faculdade de Medicina, Universidade de São Paulo, Ribeirão Preto, Brazil, E-mail: email@example.com. E. Javier Pretell, Cysticercosis Unit, Instituto Nacional de Ciencias Neurológicas, Lima, Peru, and Department of Neurology, Hospital Alberto Sabogal, Callao, Peru, E-mail: firstname.lastname@example.org.